This is a routine quarterly filing with no financial surprises or guidance. Monitor for future clinical trial readouts for LB-100 and Liora's LIGHT System as the primary catalysts.
Price Chart
Executive Summary
Lixte Biotechnology filed its Q1 2026 10-Q, reporting an EPS of -$0.27 with no consensus estimate available. The press release focuses on operational progress for lead compound LB-100 and the Liora proton therapy subsidiary, but provides no financial results or guidance. For a clinical-stage biotech with no revenue, this is a routine quarterly update with no material financial data to move the stock.
Key Financial Metrics
Key Facts
- EPS reported at -$0.27 for Q1 2026, no consensus estimate available
- No revenue reported — company is pre-revenue clinical-stage
- Press release contains no financial results, guidance, or material financial data
- Operational highlights: LB-100 ovarian cancer trial expanded, Liora proton therapy integration progressing
- No guidance provided; no earnings call or financial discussion in the release
Financial Impact
No financial data reported — pre-revenue clinical-stage biotech with $58M market cap
Risk Factors
- No revenue or near-term commercialization path for LB-100 or Liora
- Clinical-stage biotech with binary pipeline risk — trial failures could be catastrophic
- Low market cap ($58M) and potential for dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295466 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 16w ago | 8-K | $7.29 | awaiting T+1 | — | — |
Jun 18, 2026 18w ago | 8-K | $7.48 $7.30 | ▼ −2.41% | ▼ −0.95% | — |
Jun 16, 2026 18w ago | 8-K | $6.96 $7.61 | ▲ +9.34% | ▲ +8.56% | — |
Jun 12, 2026 19w ago | Press Release | $6.19 $6.72 | ▲ +8.56% | ▲ +6.80% | — |
Jun 4, 2026 20w ago | 8-K | $7.00 $6.65 | ▲ +5.00% | ▲ +5.23% | — |
Jun 4, 2026 20w ago | 424B5 | $7.00 $6.65 | ▲ +5.00% | ▲ +5.23% | — |
Jun 1, 2026 21w ago | 8-K | $7.21 $7.04 | ▼ −2.36% | ▼ −2.50% | — |
May 14, 2026 23w ago | Press Release | $5.16 $4.70 | ▼ −8.91% | ▼ −8.85% | — |
Apr 17, 2026 27w ago | 8-K | $3.44 $3.48 | ▲ +1.16% | ▲ +1.82% | — |
Apr 13, 2026 28w ago | Press Release | $2.93 $2.91 | ▼ −0.68% | ▼ −1.89% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers